A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

May 6, 2025

Conditions
Plaque Psoriasis
Interventions
DRUG

LY3972406

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (12)

17011

DermDox Centers for Dermatology, Camp Hill

27103

Accellacare - Winston-Salem, Winston-Salem

32789

Conquest Research, Winter Park

33134

Driven Research, Coral Gables

43215

Remington-Davis, Inc, Columbus

77004

Center for Clinical Studies, Houston

77056

Austin Institute for Clinical Research, Houston

90045

Dermatology Research Associates, Los Angeles

90404

Clinical Science Institute, Santa Monica

08520

Psoriasis Treatment Center of Central New Jersey, East Windsor

07601

Schweiger Dermatology Group, Hackensack

07033

Metropolitan Dermatology - Clark, Kenilworth

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06176768 - A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter